These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 33645846

  • 1. Accuracy of history, physical examination, cardiac biomarkers, and biochemical variables in identifying dogs with stage B2 degenerative mitral valve disease.
    Wilshaw J, Rosenthal SL, Wess G, Dickson D, Bevilacqua L, Dutton E, Deinert M, Abrantes R, Schneider I, Oyama MA, Gordon SG, Elliott J, Xia D, Boswood A.
    J Vet Intern Med; 2021 Mar; 35(2):755-770. PubMed ID: 33645846
    [Abstract] [Full Text] [Related]

  • 2. Factors associated with disease progression in dogs with presumed preclinical degenerative mitral valve disease attending primary care veterinary practices in the United Kingdom.
    Mattin MJ, Brodbelt DC, Church DB, Boswood A.
    J Vet Intern Med; 2019 Mar; 33(2):445-454. PubMed ID: 30565334
    [Abstract] [Full Text] [Related]

  • 3. Use of physical examination, electrocardiography, radiography, and biomarkers to predict echocardiographic stage B2 myxomatous mitral valve disease in preclinical Cavalier King Charles Spaniels.
    Wesselowski S, Gordon SG, Fries R, Saunders AB, Sykes KT, Vitt J, Boutet B, Häggström J, Kadotani S, Stack J, Barnett BG.
    J Vet Cardiol; 2023 Dec; 50():1-16. PubMed ID: 37913604
    [Abstract] [Full Text] [Related]

  • 4. The combined prognostic potential of serum high-sensitivity cardiac troponin I and N-terminal pro-B-type natriuretic peptide concentrations in dogs with degenerative mitral valve disease.
    Hezzell MJ, Boswood A, Chang YM, Moonarmart W, Souttar K, Elliott J.
    J Vet Intern Med; 2012 Dec; 26(2):302-11. PubMed ID: 22369312
    [Abstract] [Full Text] [Related]

  • 5. Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly - a randomised, double-blinded trial.
    Iwanuk N, Nolte I, Wall L, Sehn M, Raue J, Pilgram A, Rumstedt K, Bach JP.
    BMC Vet Res; 2019 Jul 09; 15(1):237. PubMed ID: 31288807
    [Abstract] [Full Text] [Related]

  • 6. Prognostic factors in dogs with presumed degenerative mitral valve disease attending primary-care veterinary practices in the United Kingdom.
    Mattin MJ, Boswood A, Church DB, Brodbelt DC.
    J Vet Intern Med; 2019 Mar 09; 33(2):432-444. PubMed ID: 30357909
    [Abstract] [Full Text] [Related]

  • 7. Comparison of N-terminal pro-atrial natriuretic peptide and three cardiac biomarkers for discriminatory ability of clinical stage in dogs with myxomatous mitral valve disease.
    Ogawa M, Hori Y, Kanno N, Iwasa N, Toyofuku T, Isayama N, Yoshikawa A, Akabane R, Sakatani A, Miyakawa H, Hsu HH, Miyagawa Y, Takemura N.
    J Vet Med Sci; 2021 Apr 24; 83(4):705-715. PubMed ID: 33551383
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of new and old biomarkers in dogs with degenerative mitral valve disease.
    Klein S, Nolte I, Granados-Soler JL, Lietz P, Sehn M, Raue JF, Rohn K, Packeiser EM, Bach JP.
    BMC Vet Res; 2022 Jul 02; 18(1):256. PubMed ID: 35780161
    [Abstract] [Full Text] [Related]

  • 9. The predictive value of clinical, radiographic, echocardiographic variables and cardiac biomarkers for assessing risk of the onset of heart failure or cardiac death in dogs with preclinical myxomatous mitral valve disease enrolled in the DELAY study.
    Borgarelli M, Ferasin L, Lamb K, Chiavegato D, Bussadori C, D'Agnolo G, Migliorini F, Poggi M, Santilli RA, Guillot E, Garelli-Paar C, Toschi Corneliani R, Farina F, Zani A, Dirven M, Smets P, Guglielmini C, Oliveira P, Di Marcello M, Porciello F, Crosara S, Ciaramella P, Piantedosi D, Smith S, Vannini S, Dall'Aglio E, Savarino P, Quintavalla C, Patteson M, Silva J, Locatelli C, Baron Toaldo M.
    J Vet Cardiol; 2021 Aug 02; 36():77-88. PubMed ID: 34118562
    [Abstract] [Full Text] [Related]

  • 10. Quality of Life Score as a Predictor of Death in Dogs with Degenerative Mitral Valve Disease.
    Strunz CMC, Marcondes-Santos M, Takada JY, Fragata FS, Mansur AP.
    Arq Bras Cardiol; 2017 Apr 02; 108(4):347-353. PubMed ID: 28380134
    [Abstract] [Full Text] [Related]

  • 11. Proteomics reveals plasma protein SERPINH1 as a potential diagnostic biomarkers for myxomatous mitral valve disease stage B2.
    Zhou Q, Wu Z, Li L, Zhou H, Chen Y, Guo S, Guo Y, Ma X, Zhang J, Feng W, Cui X, Qiu C, Xu M, Deng G.
    J Proteomics; 2023 Jun 30; 282():104924. PubMed ID: 37146676
    [Abstract] [Full Text] [Related]

  • 12. Biologic variability in NT-proBNP and cardiac troponin-I in healthy dogs and dogs with mitral valve degeneration.
    Ruaux C, Scollan K, Suchodolski JS, Steiner JM, Sisson DD.
    Vet Clin Pathol; 2015 Sep 30; 44(3):420-30. PubMed ID: 26108974
    [Abstract] [Full Text] [Related]

  • 13. Plasma N-terminal pro-B-type natriuretic peptide concentration helps to predict survival in dogs with symptomatic degenerative mitral valve disease regardless of and in combination with the initial clinical status at admission.
    Serres F, Pouchelon JL, Poujol L, Lefebvre HP, Trumel C, Daste T, Sampedrano CC, Gouni V, Tissier R, Hawa G, Chetboul V.
    J Vet Cardiol; 2009 Dec 30; 11(2):103-21. PubMed ID: 19850546
    [Abstract] [Full Text] [Related]

  • 14. Prediction of first onset of congestive heart failure in dogs with degenerative mitral valve disease: the PREDICT cohort study.
    Reynolds CA, Brown DC, Rush JE, Fox PR, Nguyenba TP, Lehmkuhl LB, Gordon SG, Kellihan HB, Stepien RL, Lefbom BK, Meier CK, Oyama MA.
    J Vet Cardiol; 2012 Mar 30; 14(1):193-202. PubMed ID: 22366568
    [Abstract] [Full Text] [Related]

  • 15. Renal resistive index in 55 dogs with degenerative mitral valve disease.
    Chetboul V, Daste T, Gouni V, Concordet D, Trehiou-Sechi E, Serres F, Pouchelon JL, Germain CA, Layssol-Lamour C, Lefebvre HP.
    J Vet Intern Med; 2012 Mar 30; 26(1):101-8. PubMed ID: 22111692
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of plasma N-terminal pro-B-type natriuretic peptide concentrations in dogs with and without cardiac disease.
    Ettinger SJ, Farace G, Forney SD, Frye M, Beardow A.
    J Am Vet Med Assoc; 2012 Jan 15; 240(2):171-80. PubMed ID: 22217025
    [Abstract] [Full Text] [Related]

  • 17. Association of plasma N-terminal pro-B-type natriuretic peptide concentration with mitral regurgitation severity and outcome in dogs with asymptomatic degenerative mitral valve disease.
    Chetboul V, Serres F, Tissier R, Lefebvre HP, Sampedrano CC, Gouni V, Poujol L, Hawa G, Pouchelon J-.
    J Vet Intern Med; 2009 Jan 15; 23(5):984-94. PubMed ID: 19572913
    [Abstract] [Full Text] [Related]

  • 18. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
    Wolf J, Gerlach N, Weber K, Klima A, Wess G.
    Vet Clin Pathol; 2013 Jun 15; 42(2):196-206. PubMed ID: 23614733
    [Abstract] [Full Text] [Related]

  • 19. DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study.
    Borgarelli M, Ferasin L, Lamb K, Bussadori C, Chiavegato D, D'Agnolo G, Migliorini F, Poggi M, Santilli RA, Guillot E, Garelli-Paar C, Toschi Corneliani R, Farina F, Zani A, Dirven M, Smets P, Guglielmini C, Oliveira P, Di Marcello M, Porciello F, Crosara S, Ciaramella P, Piantedosi D, Smith S, Vannini S, Dall'Aglio E, Savarino P, Quintavalla C, Patteson M, Silva J, Locatelli C, Baron Toaldo M.
    J Vet Cardiol; 2020 Feb 15; 27():34-53. PubMed ID: 32032923
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs.
    Atkinson KJ, Fine DM, Thombs LA, Gorelick JJ, Durham HE.
    J Vet Intern Med; 2009 Feb 15; 23(6):1190-6. PubMed ID: 19780931
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.